Viralgen specializes in the production of AAV gene therapy vectors using our proprietary suspension, triple transfection Pro10™ platform. Pro10™ is a unique high yield universal system that can produce all serotypes and chimeric forms of rAAV. The Pro10TM process utilizes a scalable upstream and robust purification process.
Scale and cGMP Offerings:
Clinical
2L scale: feasibility study and manufacturability assessment.
50L scale: non-GMP material to supply Toxicology/biodistribution studies, used as reference material or to start your stability studies.
250L/500L scales: Viralgen maintains 4 independent state-of-the-art cGMP suites, providing the capability to continuously manufacture 4 different products simultaneously. Viralgen uses 250L and 500L single-use stirred-tank bioreactors in manufacturing.
Commercial
2000L scale: Viralgen offers up to 2000L in each of our 9 suites for late phase and commercial manufacturing.